Division of Experimental Cardiology, Department of Cardiology, Thoraxcenter, Cardiovascular Research School COEUR, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Pharmacol Res. 2013 Jan;67(1):10-7. doi: 10.1016/j.phrs.2012.09.011. Epub 2012 Oct 9.
Uridine adenosine tetraphosphate (Up4A) has been identified as an endothelium-derived contracting factor, which acts through purinergic P2X and P2Y receptors. Since the coronary vascular actions of Up4A are unknown, we investigated the vasoactive profile of Up4A in coronary microvessels, and studied the involvement of purinergic receptor subtypes. Studies were performed in isolated porcine coronary small arteries (diameter∼250 μm), with and without endothelial denudation, mounted on a Mulvany wire myograph. Purinergic receptor expression was assessed by real-time PCR. Up4A (10(-9)-10(-5) M) failed to induce contraction at basal tone, but produced concentration-dependent vasorelaxation in precontracted microvessels. Up4A was slightly less potent than adenosine, ATP, and ADP in producing vasorelaxation, but significantly more potent than UTP and UDP. mRNA expression of P2X(4), P2Y(1), P2Y(2), P2Y(4), P2Y(6) and A(2A), but not P2X(1), receptors was observed. Up4A-induced vasodilation was unaffected by non-selective P2 receptor antagonist PPADS, P2X(1) antagonist MRS2159, P2Y(1) antagonist MRS2179 and P2Y(6) antagonist MRS2578, but was markedly attenuated by non-selective P1 receptor antagonist 8PT and A(2A) antagonist SCH58261. Up4A-induced vasodilation was not affected by ectonucleotidase inhibitor ARL67156, suggesting that A(2A) stimulation was not the result of Up4A breakdown to adenosine. Up4A-induced vasodilation was blunted in denuded vessels; additional A(2A) receptor blockade further attenuated Up4A-induced vasodilation, suggesting that A(2A) receptor-mediated vasodilation is only partly endothelium-dependent. In conclusion, Up4A exerts a vasodilator rather than a vasoconstrictor influence in coronary microvessels, which is mediated via A(2A) receptors and is partly endothelium-dependent.
尿苷腺苷四磷酸(Up4A)已被鉴定为一种内皮衍生的收缩因子,通过嘌呤能 P2X 和 P2Y 受体发挥作用。由于 Up4A 对冠状动脉的作用尚不清楚,我们研究了 Up4A 在冠状动脉微血管中的血管活性特征,并研究了嘌呤能受体亚型的参与情况。研究在分离的猪冠状动脉小动脉(直径约 250μm)中进行,这些小动脉有无内皮剥脱,并安装在 Mulvany 线描记器上。通过实时 PCR 评估嘌呤能受体的表达。Up4A(10(-9)-10(-5) M)在基础张力下不能引起收缩,但在预收缩的微血管中产生浓度依赖性的血管舒张。Up4A 在产生血管舒张方面的效力略低于腺苷、ATP 和 ADP,但明显强于 UTP 和 UDP。观察到 P2X(4)、P2Y(1)、P2Y(2)、P2Y(4)、P2Y(6)和 A(2A)的 mRNA 表达,但没有 P2X(1)受体。Up4A 诱导的血管舒张不受非选择性 P2 受体拮抗剂 PPADS、P2X(1)拮抗剂 MRS2159、P2Y(1)拮抗剂 MRS2179 和 P2Y(6)拮抗剂 MRS2578 的影响,但被非选择性 P1 受体拮抗剂 8PT 和 A(2A)拮抗剂 SCH58261 明显减弱。Up4A 诱导的血管舒张不受外核苷酸酶抑制剂 ARL67156 的影响,这表明 Up4A 分解为腺苷不是 A(2A)刺激的结果。在剥脱血管中,Up4A 诱导的血管舒张减弱;额外的 A(2A)受体阻断进一步减弱了 Up4A 诱导的血管舒张,表明 A(2A)受体介导的血管舒张仅部分依赖于内皮。总之,Up4A 在冠状动脉微血管中产生舒张作用而不是收缩作用,这是通过 A(2A)受体介导的,部分依赖于内皮。